Dorsal Root Ganglion (DRG) Stimulation Portfolio

Axium™ Neurostimulator System Implantable Pulse Generator (IPG) and SlimTip™ Lead

Portfolio Overview

  • Introducing a clinically superior neuromodulation therapy for focal chronic intractable pain due to CRPS1
  • Delivering superior, stable pain relief1
  • Expanding your ability to treat more patients with better results


DRG stimulation gives you the power to treat more patients with focal chronic intractable pain due to CRPS* more effectively than ever before. 

The Science Behind the DRG

The dorsal root ganglion (DRG) plays a critical role in the development and maintenance of chronic pain.2,3 It contains cell bodies of primary sensory neurons that undergo pathophysiologic changes underlying in chronic pain.4,5 The DRG’s unique pain processes and its anatomical considerations make it an ideal interventional target to treat various focal chronic intractable pain conditions.

The DRG has emerged as an exciting target for the management of focal intractable chronic pain.

Superior Pain Relief for Focal Chronic Intractable Pain

Conventional tonic SCS has been successfully used since 1967 to manage chronic, intractable pain in the trunk and/or limbs.5 But for pain locations outside of or more focal than the trunk and/or limbs—as seen in chronic intractable pain conditions—conventional tonic SCS has been less successful or has resulted in extraneous stimulation.1

Today there is a better solution: stimulating the dorsal root ganglion (DRG) has been clinically proven to achieve pain relief in focal chronic intractable pain conditions of the lower limbs.

Learn more about the Axium™ Neurostimulator System, the only FDA-approved system specifically designed to stimulate the DRG.

Infographic shows decrease in pain in patients who receive stimulation with DRG therapy
Physician writing on clipboard

ACCURATE Study: Proof That DRG Therapy Works 

The ACCURATE study is the largest randomized, controlled neuromodulation trial conducted in CRPS patients with lower limb pain to provide evidence of safety and efficacy in the United States. 

The data from the ACCURATE study suggests that DRG stimulation may offer a meaningful treatment aid for patients suffering from chronic pain conditions who are currently underserved by traditional SCS.

Read more about the study:
PDF ACCURATE Clinical Highlights (164 kb)

More Clinical Evidence

Axium™ Neurostimulator System

St. Jude Medical offers the only FDA-approved therapy system to stimulate the dorsal root ganglion (DRG)—the Axium™ Neurostimulator System. Comprised of a specially engineered stimulation lead and lead delivery technology, the Axium system is designed to precisely deliver stimulation and optimize a patient’s unique pain therapy requirements.

See how our technology empowers you to treat patients with focal chronic intractable pain in the lower limbs due to CRPS* with the Axium™ Neurostimulator System

Front view of Axium™ Neurostimulator System IPG for dorsal root ganglion (DRG) stimulation
Diagrammed drawing of the lumbar vertebrae (lower spinal cord)

Transforming the Treatment of Chronic Pain

At St. Jude Medical, our patient-focused approach to pain management is inspired by the care needs and challenges of patients with chronic pain. We offer the broadest range of therapies across the continuum of care to help physicians like you tailor your approach. Our investments in research, technology and partnerships can improve therapy outcomes and increase treatment options.

Partner with us to treat more patients with better results and transform the lives of more patients suffering from chronic pain.

Learn more about our approach to chronic pain


*Complex Regional Pain Syndrome (CRPS I/II, Causalgia): According to the National Health Service (NHS), pain associated with CRPS is typically caused by an injury and is usually confined to one limb, but can spread to other parts of the body. Pain symptoms include burning, stabbing or stinging, but may also include a tingling sensation and numbness. Many CRPS patients also report symptoms of hyperalgesia (extreme sensitivity to pain) and/or allodynia (experiencing pain from a very light touch).
**As studied in the ACCURATE clinical trial.
1. Levy, R., & Deer, T. (2015). A prospective, randomized, multi-center controlled clinical trial to assess the safety and efficacy of the Spinal Modulation Axium™ Neurostimulator System in the treatment of chronic pain. Presented at the meeting of the North American Neuromodulation Society (NANS), Las Vegas, NV.
2. Pope, J. E., Deer, T. R., & Kramer, J. (2013). A systematic review: Current and future directions of dorsal root ganglion therapeutics to treat chronic pain. Pain Medicine, 14(10), 1477-1496.
3. Sapunar, D., Kostic, S., Banozic, A., & Puljak, L. (2012). Dorsal root ganglion—a potential new therapeutic target for neuropathic pain. Journal of Pain Research, 5, 31-38.
4. Devor, M. (1999). Unexplained peculiarities of the dorsal root ganglion. Pain, 82(Suppl. 1), S27-S35.
5. Chung, J. M., & Chung, K., (2002). Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Practice, 2(2), 87-97.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.